Advantage Alpha Capital Partners LP Buys New Position in Guardant Health, Inc. (NASDAQ:GH)

Advantage Alpha Capital Partners LP purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 14,937 shares of the company’s stock, valued at approximately $343,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of GH. JNBA Financial Advisors acquired a new stake in Guardant Health during the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Guardant Health during the third quarter worth approximately $34,000. Quarry LP acquired a new stake in shares of Guardant Health during the second quarter worth $44,000. Canton Hathaway LLC acquired a new stake in shares of Guardant Health during the second quarter worth $59,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Guardant Health in the 2nd quarter valued at $71,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

NASDAQ:GH opened at $34.37 on Wednesday. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. The firm has a 50 day simple moving average of $24.42 and a 200-day simple moving average of $27.06. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $37.04.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The business had revenue of $191.48 million during the quarter, compared to analysts’ expectations of $170.49 million. During the same period in the prior year, the firm earned ($0.73) EPS. Guardant Health’s revenue for the quarter was up 33.9% on a year-over-year basis. On average, equities research analysts anticipate that Guardant Health, Inc. will post -3.38 earnings per share for the current year.

Insider Buying and Selling at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on GH shares. Piper Sandler lifted their price objective on Guardant Health from $30.00 to $34.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. JPMorgan Chase & Co. lifted their price target on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. The Goldman Sachs Group increased their price objective on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. TD Cowen boosted their target price on shares of Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Finally, Citigroup upped their price target on shares of Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $40.60.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.